Portfolio company Inivata, a global clinical cancer genomics company using circulating tumor DNA (ctDNA) analysis to improve personalized healthcare in oncology, has announced the launch of its US clinical validation study (INI-001) in non-small cell lung cancer (NSCLC).
INI-001 is a prospective study to compare Inivata’s targeted molecular profiling liquid biopsy platform against tissue based profiling in patients with advanced NSCLC. The study will take place in over 30 centres in the US and led by co-principal investigators Ramaswamy Govindan, MD and Ed Kim, MD. Inivata has selected Vector Oncology as the Clinical Research Organization for the study.
Clive Morris, MD, Inivata’s Chief Medical Officer, said:
“We are thrilled to partner with outstanding national cancer centers across the US to launch our INI-001 study, which will correlate our highly sensitive ctDNA analysis from a simple blood draw with standard of care tissue biopsies. These data will be a key part of the evidence to support the use of Inivata’s proprietary platform in helping physicians improve the clinical outcomes of their cancer patients.”